Eight new medicines walked away with a positive opinion from the European Medicines Agency’s human medicines committee at its meeting from 18 to 21 May, a batch that captured both the scientific direction of the moment and the commercial pressures driving it. Alongside the new approvals the committee recommended thirteen extensions to medicines already on the market, the unglamorous work of widening the reach of drugs that have already cleared the regulatory bar.
The recommendation drawing the most attention was not a new molecule at all. The committee backed an extension for Wegovy, the semaglutide weight-management treatment, to add a daily oral tablet as an alternative to the weekly injection. It would be the first glucagon-like peptide-1 receptor agonist for weight management developed in pill form, a milestone that matters less for the science than for access. Injectables require cold storage, needles and a degree of patient confidence that a tablet does not, and the shift toward oral dosing could broaden a market already straining under demand. Whether health systems can afford that broadening is a separate question European payers have yet to answer convincingly.
The genuinely novel approvals leaned toward serious and often neglected conditions. Jascayd, with the active substance nerandomilast, received a positive opinion for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, two diseases marked by relentless and irreversible scarring of lung tissue and few effective treatments. Vijoice, containing alpelisib, was recommended for a conditional marketing authorisation in patients with severe PIK3CA-related overgrowth spectrum disorders, a rare group of conditions where the regulatory willingness to authorise on incomplete but promising evidence reflects how little else is available.
Conditional authorisations of that kind illustrate the balancing act the committee performs. Granting market access before the full evidence package is complete accepts more uncertainty in exchange for speed, a trade-off justified when patients have no alternative and the disease is grave. The mechanism carries an obligation to keep generating data, and the agency’s credibility rests on enforcing that follow-through rather than letting provisional approvals quietly harden into permanent ones.
None of these opinions is the final word. The recommendations now pass to the European Commission, which issues legally binding decisions valid across the bloc, a step that usually takes two to three months. Only then can the medicines reach patients, and national pricing and reimbursement negotiations add further delay that varies widely between member states.
The May output also lands against a larger backdrop. The bloc has just completed the most sweeping overhaul of its pharmaceutical legislation in over two decades, with final texts published earlier this year and a transition period running to 2028 while national laws are aligned. That reform reshapes incentives for innovation, the structure of the agency’s scientific committees, and the rules on shortages and rare-disease medicines. Seen in that light, a single month of recommendations is a snapshot of a system being rebuilt around it, one positive opinion at a time, even as the framework that governs them all is still settling into place.
